Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112073 · ClinicalTrials.gov registry record · Phase 2
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT00112073: Completed Phase 2 study of Alzheimers Disease, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00112073 is a Phase 2 study of Alzheimers Disease that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 234 participants, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00112073, a Phase 2 study of Alzheimers Disease, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
Conditions Studied
Interventions
- OTHER placebo
- DRUG bapineuzumab
Study Locations (20)
California
- UC Irvine - Irvine
- Pharmacology Research Institute - Los Alamitos
- Pharmacology Research Institute - Northridge
- UCSD Shiley-Marcos Alzheimer's Disease Research Center - San Diego
- Memory & Aging Center, UCSF - San Francisco
Florida
- Brain Matters Research, Inc. - Delray Beach
- Mayo Clinic - Department of Neurology - Jacksonville
New York
- Sergievsky Center, Columbia University - New York
- University of Rochester / Monroe Community Hospital - Rochester
Arizona
- Cleo Roberts Center for Clinical Research / Sun Health Research Institute - Sun City
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- Rush Presbyterian St. Luke's Medical Center - Chicago
Indiana
- Department of Neurology - Indiana University Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00112073 record still lists
NCT00112073 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00112073 names 20 study sites across 14 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00112073 about?
NCT00112073 is a clinical study titled "AAB-001 in Patients With Mild to Moderate Alzheimer's Disease". The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
What is the current status of trial NCT00112073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2005-04. Estimated completion is 2008-12.
What conditions does trial NCT00112073 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00112073?
The interventions under investigation include: placebo (OTHER), bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT00112073?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00112073 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00112073's enrollment target sits among peer trials
234 52nd of 147 higher than 96 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia